Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma

Haematologica

Volumn 97, Issue 4, 2012, Pages 572-578

  Xu, Chuanhui ^a   Plattel, Wouter ^a   van den Berg, Anke ^a   Rüther, Nele ^b   Huang, Xin ^a   Wang, Miao ^c   de Jong, Debora ^a   Vos, Hans ^a   van Imhoff, Gustaaf ^a   Viardot, Andreas ^d   Möller, Peter ^b   Poppema, Sibrand ^a   Diepstra, Arjan ^a   Visser, Lydia ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF ULM   (Germany)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

C Met; Classical Hodgkin's lymphoma; Hepatocyte growth factor; Prognosis

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (3 CHLOROPHENYL) 3 [3, 5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2, 3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PROTEIN KINASE B; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL CYCLE ARREST; CHILD; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; TUMOR CELL; TUMOR GROWTH; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; CELL CYCLE; CELL LINE; CHILD; FEMALE; GENE EXPRESSION; HEPATOCYTE GROWTH FACTOR; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84859448770     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.056101     Document Type: Article

References (32)

1. Kanzler H, Küppers R, Hansmann ML, Rajewski K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;184 (4):1495-1505.
2. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009;9(1):15-27.
3. Renné C, Willenbrock K, Küppers R, Hansmann ML, Bräuninger A. Autocrine and paracrine activated receptor tyrosine kinases in classical Hodgkin lymphoma. Blood. 2005;105(10):4051-4059.
4. Klimm B, Engert A. Combined modality treatment of Hodgkin's lymphoma. Cancer J. 2009;15(2):143-149.
5. Hasenclever D, Diehl V. A Prognostic score for advanced Hodgkin's disease. N Engl J Med. 1998;339(21):1506-1514.
6. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macro - phages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362(10): 875-885.
7. Diepstra A, van Imhoff GW, Karim-Kos HE, van den Berg A, te Meerman GJ, Niens M, et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol. 2007; 25 (21):3101-3108.
8. Diepstra A, van Imhoff GW, Schaapveld M, Karim-Kos H, van den Berg A, Vellenga E, et al. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol. 2009;27(23): 3815-3821.
9. Ma PC, Maulik G, Christensen J, Salgia R. C- Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003;22(4):309-325.
10. Comoglio PM, S Giordano, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7(22):504-516.
11. Kawano R, Ohsima K, Karube K, Yamaguchi T, Kohno S, Suzumiya J, et al. Prognostic significance of hepatocyte growth factor and c-MET expression in patients with diffuse large B-cell lymphoma. Br J Haematol. 2004;127(3):305-307.
12. Cheng HL, Trink B, Tzai TS, Liu HS, Chan SH, Ho CL, et al. Overexpression of c-met as a Prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol. 2002;20(6): 1544-1550.
13. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 2005;113(4):678-682.
14. Lee CT, Chow N, Su PF, Lin SC, Lin PC, Lee JC. The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer. Dis Colon Rectum. 2008;51(8):1268-1274.
15. Ayhan A, Ertunc D, Tok EC, Ayhan A. Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance. Int J Gynecol Cancer. 2005;15 (4):618-623.
16. Sattler M, Pride YP, Ma P, Gramlich JL, Chu SC, Quinnan LA, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 2003; 63(20):5462-5469.
17. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, et al. Functional expression and mutations of c- Met and its therapeutic inhibition with SU11274 and small interfering RNA in nonsmall cell lung cancer. Cancer Res. 2005;65 4):1479-1488.
18. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006;66(1): 352-361.
19. Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, et al. C-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res. 2007;13(8):2246-2253.
20. Weimar IS, de Jong D, Muller EJ, Nakamura T, van Gorp JM, de Gast GC, et al. Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via alpha 4beta 1 and alpha 5beta 1 Integrins. Blood. 1997;89(3):990-1000.
21. Teofili L, di Febo AL, Pierconti F, Maggiano N, Bendandi M, Rutella S, et al. Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood. 2001;97(4):1063-1069.
22. Jücker M, Günther A, Gradl G, Fonatsch C, Krüger G, Diehl V, et al. The Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma. Leuk Res. 1994; 18(1):7-16.
23. Pons E, Uphoff CC, Drexler HG. Expression of hepatocyte growth factor and its receptor c-met in human leukemia-lymphoma cell lines. Leukemia Res. 1998; 22(9):797-804.
24. Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. Leuk Lymphoma. 1993;9(1/2):1-25.
25. Mader A, Bruderlein S, Wegener S, Melzner I, Popov S, Muller-Hermelink HK, et al. UHO1, a new cell line derived from a primary refractory classical Hodgkin lymphoma. Cytogenet Genome Res. 2007;119(3/4):204-210.
26. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4 (12):915-925.
27. Nakopoulou L, Gakiopoulou H, Keram-Poulos A, Giannopoulou I, Athanassiadou P, Mavrommatis J, et al. c-Met tyrosine kinase receptor expression is associated with abnormal β-catenin expression and favourable prognostic factors in invasive breast carcinoma. Histopathol. 2000;36(4): 313-325.
28. Uddin S, Hussain AR, Ahmed M, Al-Dayel F, Bu R, Bavi P, et al. Inhibition of c-Met is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. Lab Invest. 2010;90(9):1346-1356.
29. Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med. 1999;5(2):226-230.
30. Poppema S. Immunobiology and pathophysiology of Hodgkin lymphomas. Am Soc Hematol Educ Program. 2005: 231-238.
31. Beilmann M, Vande Woude GF, Dienes HP, Schirmacher P. Hepatocyte growth factorstimulated invasiveness of monocytes. Blood. 2000;95(12):3964-3969.
32. Moransard M, Sawitzky M, Fontana A, Suter T. Expression of the HGF receptor c- Met by macrophages in experimental autoimmune encephalomyelitis. Glia. 2010; 58(5):559-571.